Edwards Lifesciences Corp (EW) Financials
Key financial figures for Edwards Lifesciences Corp (Q2 2026).
Edwards Lifesciences grew Q2 2026 net sales 13.6% to $1.74 billion (12.5% constant currency), led by TMTT sales up 47.7% to $198.6 million, and raised full-year 2026 guidance for the second consecutive quarter. Q2 2026 net sales were $1.74 billion, up 13.6% year-over-year (12.5% constant currency), which management called 'stronger-than-expected'; GAAP diluted EPS was $0.42 (down from $0.56) and adjusted EPS was $0.78, flat versus Q1 2026's $0.78. TAVR sales grew 11.3% YoY to $1.26 billion (10.5% CC), helped by the exit of a competitor in Q2 2025 and continued SAPIEN 3 Ultra RESILIA adoption; growth rates were similar in the US and OUS. On the outlook: Edwards raised full-year 2026 guidance after Q2: total company constant-currency sales growth to 10-11% (from 9-11%), TAVR constant-currency sales growth to 8-9% (from 7-9%), and TMTT sales to $760-$780 million (from $740-$780 million). Full-year 2026 total sales are now expected at $6.6-$6.9 billion, with TAVR sales of $4.75-$5.0 billion. Adjusted EPS guidance was reaffirmed at $2.95-$3.05 (growing 17% at the midpoint) despite the company now assuming the high end of its 16-19% effective tax rate range. For Q3 2026, Edwards projects total sales of $1.63-$1.71 billion and adjusted EPS of $0.71-$0.77. Figures are for Q2 2026, as Edwards Lifesciences Corporation reported them.
- Revenue
- $1.7B
- Net Income
- $241M
- EPS
- $0.42
- Total Assets
- $13.9B
- Operating Cash Flow
- $652M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $1.7B | $242M | $0.42 | 29.84% | $585M |
| Q1 FY2026 | $1.6B | $381M | $0.66 | 31.22% | -$21M |
| Q4 FY2025 | $1.6B | $91M | $0.16 | 23.59% | $354M |
| Q3 FY2025 | $1.6B | $291M | $0.50 | 27.37% | $516M |
| Q2 FY2025 | $1.5B | $330M | $0.56 | 28.12% | $241M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $6.1B | $1.1B | $1.83 | 26.97% | $1.3B |
| FY2024 | $5.4B | $4.2B | $6.97 | 25.35% | $290M |
| FY2023 | $5.0B | $1.4B | $2.30 | 28.49% | $630M |
Frequently asked questions
What was Edwards Lifesciences Corporation's revenue last quarter?
Edwards Lifesciences Corporation reported revenue of $1.74 billion for Q2 FY2026, up 13.6% from the same period a year earlier.
Is Edwards Lifesciences Corporation profitable?
Yes. Edwards Lifesciences Corporation reported net income of $241.9 million for Q2 FY2026, a net margin of 13.89% on revenue.
How has Edwards Lifesciences Corporation's margin trended?
Operating margin was 29.84% in Q2 FY2026, compared with 28.12% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Edwards Lifesciences Corporation generate?
Edwards Lifesciences Corporation generated free cash flow of $585.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Edwards Lifesciences Corp on SentiSense, with up to forty quarters and twenty fiscal years of history.